SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid intense community speculation of an impending short squeeze, driven by perceived technical breakouts and widespread anticipation of strategic announcements or positive earnings from Chairman Ryan Cohen, with many noting its resilience in a volatile market.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX is trending due to a cluster of recent positive developments including a $40 million private placement, new strategic partnerships with GSK and DNDi, and an analyst upgrade, sparking intense community debate between aggressive bulls targeting significant price appreciation and bears pointing to past trial setbacks and potential dilution.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating Middle East tensions, particularly the Strait of Hormuz closure and production cuts by key oil producers, have sent crude prices soaring. Community discussion is highly polarized, with some anticipating further parabolic gains, while others foresee a sharp pullback as G7 nations consider a significant strategic oil reserve release and potential escort missions to reopen the strait.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating Middle East tensions and surging oil prices fuel expectations for increased market volatility, with the community sharply divided between those buying dips as a market hedge and others anticipating a "VIX crush" or inherent decay in the leveraged ETF.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 trial data for its bladder cancer candidate, NDV-01, which reported a durable 76% complete response rate and reinforced plans for Phase 3 trials. The company's recently announced $160 million private placement to fund further development is also a key talking point, with the community actively discussing the drug's potential and the financing's implications for its future trajectory.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

Aureus Greenway Holdings is trending due to its announced merger with drone manufacturer Powerus, backed by Eric and Donald Trump Jr., signaling a significant pivot into the defense-drone sector amid rising military tech demand. Community discussion reflects strong enthusiasm for potential government contracts and short squeeze opportunities, while also acknowledging concerns around the stated merger valuation and recent share dilution.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is highly active as crude oil experiences significant volatility, with many traders anticipating a sharp downturn after recent geopolitical tensions led to price surges. The community is aggressively buying this inverse ETF, viewing current oil levels as overbought and primed for a major correction.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending after resolving its legal dispute with Novo Nordisk and announcing a partnership to offer FDA-approved GLP-1 weight-loss medications on its platform. This development has largely eliminated the previous bear thesis, fueling significant short-squeeze speculation and community discussion about the company's long-term potential as a digital health and wellness platform.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as it staged a notable rebound from an early dip driven by escalating Middle East tensions and oil price spikes, surprising many bears who had anticipated a market collapse amid reports of oil tankers transiting the Strait of Hormuz and discussions of G7 reserve releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Microvision (NASDAQ:MVIS) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Microvision from a "hold" rating to a "strong sell" rating in a report on Saturday...

<ul class="summary-bullets"><li>Microvision’s Q4 revenue slumped 88% year-on-year to $0.2 million with a loss per share of $0.12.</li><li>D. Boral Capital analyst Jesse Sobelson downgraded MicroVision to ‘Hold’ from ‘Buy’.</li><li>The analyst said the results underscore ongoing uncertainty around near-term sales growth and continued spending pressures.&nbsp;</li></ul>MicroVision Inc. (MVIS) saw its outlook turn more cautious on Wall Street after D. Boral Capital’s downgrade raised concerns about the company’s financial trajectory and uncertain revenue prospects.&nbsp;The shift follows the firm’s fourth-quarter (Q4) results. Microvision’s Q4 revenue slumped 88% year-on-year (YoY) to $0.2 million with a loss per share (EPS) of $0.12. Both revenue and EPS missed the analysts’ consensus estimates of $3 million and a loss per share of $0.05, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Concerns Around Revenue Visibility</h2>D. Boral Capital analyst Jesse Sobelson downgraded MicroVision to ‘Hold’ from ‘Buy’ after reviewing the company’s Q4 performance and financial outlook. The analyst said the results underscore ongoing uncertainty around near-term sales growth and continued spending pressures.&nbsp;Sobelson said the company currently provides limited clarity about when meaningful revenue growth might materialize. While MicroVision has positioned its technology for potential applications in advanced sensing and automotive systems, the analyst suggested that tangible commercial traction has yet to fully emerge.<a href="https://stocktwits.com/symbol/MVIS/news">MicroVision stock</a> traded over 19% lower at noon Thursday. On Stocktwits, retail sentiment around the stock shifted to ‘neutral’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_121054_png_4dd819fb08.webp" alt="MVIS’s Sentiment Meter and Message Volume as of 12:00 p.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="929" height="102"></figure><h2 class="st-heading-2">Financial Performance And Liquidity</h2>The company recorded a quarterly net loss of $37.8 million, including significant non-cash impairment and inventory charges. By comparison, the loss for the prior-year quarter stood at $31.2 million.&nbsp;The lidar developer outlined a series of operational initiatives, including early product shipments, new technology integration, and plans to streamline costs as it prepares for future growth.MicroVision ended the year with approximately $74.8 million in cash and investment securities. In February 2026, the company further strengthened its balance sheet by issuing $43 million in senior secured convertible notes under an agreement with High Trail Capital.MVIS stock has declined by more than 53% over the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-ceo-david-ellison-says-wbd-deal-positions-it-to-compete-more-effectively-globally-report/cZdQDDQRI3k">Paramount Skydance CEO David Ellison Says WBD Deal Positions It To Compete More Effectively Globally: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MicroVision logo is seen displayed on a smartphone screen. 

MVIS Plummets Over 20%: D. Boral Capital Downgrades The Stock Citing Revenue Uncertainty And Wider Q4 Loss

Analyst Jesse Sobelson said the company currently provides limited clarity about when meaningful revenue growth might materialize.

Equity

Analyst Jesse Sobelson said the company currently provides limited clarity about when meaningful revenue growth might materialize.


Microvision's (MVIS) "Hold" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "hold" rating on shares of Microvision in a report on Thursday...

Microvision Q4 Earnings Call Highlights

Microvision (NASDAQ:MVIS) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what Chief Executive Officer Glen DeVos described as a shift in the lidar industry...

Microvision (NASDAQ:MVIS) Releases Earnings Results, Misses Estimates By $0.07 EPS

Microvision (NASDAQ:MVIS - Get Free Report) posted its earnings results on Wednesday. The electronics maker reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.07...

Insights Ahead: Microvision's Quarterly Earnings

MicroVision Calls It Lidar 2.0, Highlights Luminar Deal and First Shipment to Europe

Microvision (NASDAQ:MVIS) executives used a recent webinar to outline what CEO Glen De Vos described as the lidar industry's shift from a technology-proving phase to a commercialization-focused era...

Microvision (MVIS) Projected to Post Earnings on Wednesday

Microvision (NASDAQ:MVIS) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

D. Boral Capital Reiterates Buy Rating for Microvision (NASDAQ:MVIS)

D. Boral Capital restated a "buy" rating and issued a $3.00 price target on shares of Microvision in a research report on Tuesday...

D. Boral Capital reissued a "buy" rating and set a $3.00 price objective on shares of Microvision in a research report on Tuesday...

MicroVision, Inc. develops and commercializes perception solutions for autonomy and mobility applications. It offers product suite, including perception software for industrial, automotive, and defense markets; MAVIN, a MEMS-based long-range sensor capable of small object detection; MOVIA, a flash-based short- to mid-range sensor; lidar sensors for non-automotive industrial markets, such as industrial, smart infrastructure, robotics, and commercial vehicles; and reference and validation software. The company also provides engineering services in connection with hardware and software products, as well as develops custom application software. In addition, it offers industrial and automotive perception systems and advanced driver-assistance systems (ADAS); and MOSAIK suite, a validation software tool for use by OEMs and Tier 1s to validate vehicle sensors for ADAS and autonomous driving applications. The company markets its products to customers directly, through trade shows, and its website. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

Current Price	$0.5254
Prev Close	$0.5722
Open	$0.56
Dividend Yield	0.00%
50-Day Moving Average	$0.8281
Beta	2.08
Avg. Volume	4.7M
PE Ratio	-1.64

52-Week High	$1.73
52-Week Low	$0.51
Market Capitalization	$175.42M
EPS (Annual)	-$0.3477
Price to Book	3.16
Revenue Per Employee	$6,357.90

MVIS
Microvision Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MVIS News

MVISMicrovision Inc